dR. DAYAN GOODENOWE
FOUNDER, PRESIDENT & CEO - PRODROME SCIENCES, INC.
I do not believe that disease is either random or unpredictable. However, medicine, as it is currently practiced, is based upon this passive acceptance model. Passive, in that we primarily wait for disease to happen to us, and accepting in that we assume that we are powerless, in any specific way, to predict or prevent a specific disease prior to its occurrence.
The practice of medicine will not change from its current acute-care focus to a preventative-care focus by simply wishing it so. Our acute-care system, despite its faults, is practiced well and has systematically improved year after year. Each improvement must be targeted to an unmet need, be actionable, and have a measurable outcome. Only after these requirements are met will a change become accepted. This is the correct way to advance changes to any system.
My primary professional interest is the advancement of precision preventative medicine into mainstream medical practice. The achievement of this goal involves the integration and translation of various scientific and technological fields such as basic biochemistry, biomarker discovery, diagnostic technology, biostatistics, clinical trial design and execution, targeted therapeutic development, epidemiology, and healthcare economics. The prevention and treatment of neurodegenerative diseases is my primary focus.
As the founder of Prodrome Sciences Inc., my primary responsibility is to build a next-generation team of dedicated researchers and other professionals and to work with and continue to grow this team such that Prodrome Sciences Inc. can reach its ultimate goal of saving lives and improving quality of life by implementing our targeted strategy of disease prevention through prodrome detection and treatment. I am immensely proud of our founding team and consider myself fortunate to have this opportunity to build a new company with them.
Population health is not about designing and executing narrowly defined clinical trials with very strict inclusion and exclusion criteria to determine if a drug or supplement can modify carefully controlled and selected disease symptoms. These types of trials are important and invaluable to the scientific community and allow scientists to better understand certain biochemical mechanisms of disease. However, the real human population is messy. Population health is about designing and executing clinical trials for the real world and for real people living normal lives. Population health is about changing disease incidence rates and epidemiological numbers.
My research into the biochemical mechanisms of disease started in 1990. My curiosity about the biochemistry of life is as insatiable
today as it was 30 years ago. In those 30 years, I have invented and developed advanced diagnostic and bioinformatic technologies,
designed and manufactured novel and natural biochemical precursors, and identified biochemical prodromes of numerous diseases including
Alzheimer’s disease and dementia, Parkinson’s disease, multiple sclerosis, stroke, autism, amyotrophic lateral sclerosis (ALS), multiple system atrophy, schizophrenia, bipolar disorder, depression, and cancers of the colon, pancreas, ovary, breast, lung, kidney, esophagus, liver, stomach, and endometria. I strive to go beyond the diagnosis of disease and I am setting my sights on figuring out how long the human body can maintain the physical and biological functions of life.